New microtubular agents in pediatric oncology

Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT: Plantantitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus breviofolia. J Am Chem Soc 93:2325–2327, 1971. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665–667, 1979. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565, 1980. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259, 1990. Colin M, Guenard D, Gueritte-Voegelein F, et al.: Taxol derivatives, their preparation and pharmaceutical compositions containing them. Rhone-Poulenc Sante, US Patent 4814470, granted March 21, 1989 (priority date, July 17, 1986). Colin M, Guenard D, Gueritte-Voegelein F, et al.: Process for the preparation of Taxol and 10-deacetytaxol. Rhone-Poulenc Sante, US Patent 4857653, granted August 15, 1989 (priority date, July 17, 1986). Lavelle F, Fizames C, Gueritte-Voegelein F, et al.: Experimental properties of RP56976 a Taxol derivative. Proc Am Assoc Cancer Res 30:566, 1989 (abstract 2254). Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288–291, 1991. Hill BT, Whelan RDH, Shelland SH, et al.: Differential cytotoxic effects of Taxotere in a range of mammalian tumour cell lines in vitro. Ann Oncol 3:120, 1992. Riou JF, Naudin, A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164–170, 1992. Bissery MC, Guenard D, Gueritte-Voegelein F, et al.: Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845–4852, 1991. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004–1014, 1995. Huizing MT, Misser VHS, Pieter RC, Huinink WW, Veehof CHN, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Investigations 13:381–404, 1995. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643–2655, 1955. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552–9556, 1993. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32:2747–2755, 1993. Gueritte-Voegelein F, Guenard D, Lavelle F, et al.: Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992–998, 1991. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479–487, 1981. Mandredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688–696, 1982. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′ triphosphate or microtubule-associated proteins. Biochemistry 20:3247–3252, 1981. Rao S, Horwitz SB, Ringel I: Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84:785–788, 1992. Fromes Y, Gounon P, Bissery MC, et al.: Differential effects of Taxol and Taxotere (RP56976, NSC 628503) on tau and MAP2 containing microtubules. Proc Am Assoc Cancer Res 33:511, 1992 (abstract 3055). Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613–617, 1992. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–3497, 1992. Choy H, Rodriguez F, Wilcox B, et al.: Radiation sensitizing effects of Taxotere (RP56976). Proc Am Assoc Cancer Res 33:500, 1992 (abstract 2991). Choy H, Akerley W, Safran H, et al.: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682–2686, 1994. Cabral F, Wible L, Brenner S, Brinkley BR: Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97:30–39, 1983. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol mechanisms of action and resistance. Monogr Natl Canc Inst 15:55–61, 1993. Gupta RS: Taxol resistant mutants of Chinese hamsters ovary cells: genetic biochemical and cross-resistant studies. J Cell Physid 114:137–144, 1983. Roy SN, Horwitz SB: A phosphoglycoprotein associated with Taxol resistance in J7742 cells. Cancer Res 45:3856–3863, 1985. Rowinsky EK, Eisenhouer EA, Chaudhry V, Arbuck SA, Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:Suppl 3:1–15, 1993. Eisenhouer EA, Ten Bokkel Huinick WW, Swenerton K, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low-dose and long versus short infusion. J Clin Oncol 12:654–666, 1994. Huizing MT, Keuing ACF, Rosing H, et al.: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127–2135, 1993. Pazdur R, Newman RA, Newman BM, et al.: Phase I trial of Taxotere: five-day schedule. J Natl. Cancer Inst 84:1781–1788, 1992. Extra JM, Rousseau F, Bruno R, et al.: Phase I and pharmacokinetic study of Taxotere (RP56976, NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042, 1993. Wanders J, Schrijvers D, Bruntsch U, et al.: The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere studies. Proc Am Soc Clin Oncol 12:94, 1993 (abstract 1994). Irwin B, Burris H, Kuhn J, et al.: Phase I trial of a 2 and 3 hour infusion of Taxotere. Proc Am Soc Clin Oncol 12:347, 1993. Oulid-Aissa D, Behar A, Spielmann M, et al.: Management of fluid retention syndrome in patients treated with Taxotere (Docetaxel): effect of premedication. Proc Am Soc Clin Oncol 13:465, 1994 (abstract 1614). Tomiak E, Piccart MJ, Kerger J, et al.: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458–1467, 1994. Seibel N, Ames M, Ivy P, Krailo M, Reid J, Kent P, Reaman G: Phase I and pharmacokinetic study of paclitaxel in refractory leukemia: A Childrens Cancer Group Study. Proc Am Soc Clin Oncol 13:324, 1994. Hurwitz C, Relling M, Weitman SD, Ravindranath Y, Vietta TJ, Strother DR, Ragab AH, Pratt CB: Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 11:2324–2329, 1993. Donfrancesco A, Deb G, Sio L, Habetswallner D, Helson L: Phase I trial of a Q4d Taxol regimen in pediatric patients with recurrent solid tumors. Proc Am Soc Clin Oncol 13:426, 1994 (abstract 1463). Blaney S, Seibel N, O'Brien M, Mosher R, Reaman G, Poplack D, Balls F: Phase I study of Taxotere in pediatric patients. Proc Am Assoc Cancer Res 35:211, 1994 (abstract 1259). Rowinsky EK, Burke PJ, Karp JE, Tucker RA, Ettengli D, Donehower RC: Phase I and pharmacodynamic study of Taxol in refractory acute leukemia. Cancer Res 49:4640–4647, 1989. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532–538, 1994.